NASDAQ:LBPH

Longboard Pharmaceuticals (LBPH) Stock Forecast, Price & News

$7.45

-0.36 (-4.61%)

(As of 06/9/2023 ET)

Compare

Today's Range: $6.95
▼
$7.87
50-Day Range: $4.19
▼
$10.05
52-Week Range: $2.70
▼
$10.29

Volume: 181,581 shs
Average Volume: 67,266 shs
Market Capitalization: $171.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.40

Longboard Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 133.6% Upside
$17.40 Price Target
Short Interest: Healthy
0.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($2.29) to ($2.04) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

708th out of 987 stocks

Pharmaceutical Preparations Industry

342nd out of 482 stocks

3.5

Analyst's Opinion

Consensus Rating
Longboard Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.40, Longboard Pharmaceuticals has a forecasted upside of 133.6% from its current price of $7.45.
Amount of Analyst Coverage
Longboard Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.57% of the float of Longboard Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Longboard Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Longboard Pharmaceuticals has recently increased by 352.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Longboard Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Longboard Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LBPH.

3.3

News and Social Media Coverage

News Sentiment
Longboard Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Longboard Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
1 people have added Longboard Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Longboard Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.57% of the stock of Longboard Pharmaceuticals is held by insiders.
Percentage Held by Institutions
53.46% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Longboard Pharmaceuticals are expected to grow in the coming year, from ($2.29) to ($2.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Longboard Pharmaceuticals is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Longboard Pharmaceuticals is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Longboard Pharmaceuticals has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Longboard Pharmaceuticals (NASDAQ:LBPH) Stock

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Receive LBPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longboard Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LBPH Stock News Headlines

May 14, 2023 | americanbankingnews.com

Q3 2023 EPS Estimates for Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Boosted by Wedbush

May 14, 2023 | americanbankingnews.com

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Expected to Earn Q2 2023 Earnings of ($0.55) Per Share

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

May 13, 2023 | americanbankingnews.com

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) to Post Q1 2024 Earnings of ($0.72) Per Share, Wedbush Forecasts

May 13, 2023 | americanbankingnews.com

Cantor Fitzgerald Increases Longboard Pharmaceuticals (NASDAQ:LBPH) Price Target to $16.00

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Longboard Pharmaceuticals (LBPH) Buy Recommendation

May 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Services Companies: Longboard Pharmaceuticals (LBPH) and New York Times (NYT)

May 12, 2023 | finance.yahoo.com

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

June 10, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

May 12, 2023 | msn.com

Cantor Fitzgerald Maintains Longboard Pharmaceuticals (LBPH) Overweight Recommendation

May 11, 2023 | msn.com

Wedbush Reiterates Longboard Pharmaceuticals (LBPH) Outperform Recommendation

May 10, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Longboard Pharmaceuticals

May 10, 2023 | markets.businessinsider.com

Wedbush Reaffirms Their Buy Rating on Longboard Pharmaceuticals (LBPH)

May 9, 2023 | msn.com

Recap: Longboard Pharmaceuticals Q1 Earnings

May 9, 2023 | finance.yahoo.com

Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results

May 2, 2023 | americanbankingnews.com

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) to Post FY2023 Earnings of ($2.24) Per Share, B. Riley Forecasts

May 1, 2023 | finance.yahoo.com

Longboard Pharmaceuticals, Inc. (LBPH) is on the Move, Here's Why the Trend Could be Sustainable

April 28, 2023 | americanbankingnews.com

Longboard Pharmaceuticals (NASDAQ:LBPH) Coverage Initiated at B. Riley

April 28, 2023 | msn.com

B. Riley Securities Initiates Coverage of Longboard Pharmaceuticals (LBPH) with Buy Recommendation

April 14, 2023 | finance.yahoo.com

Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why

April 11, 2023 | finance.yahoo.com

Longboard Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 9, 2023 | americanbankingnews.com

Longboard Pharmaceuticals (NASDAQ:LBPH) Trading Up 13.6%

April 7, 2023 | finance.yahoo.com

Does Longboard Pharmaceuticals, Inc. (LBPH) Have the Potential to Rally 208.22% as Wall Street Analysts Expect?

April 5, 2023 | finance.yahoo.com

Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352

March 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Services Companies: Longboard Pharmaceuticals (LBPH) and Thoughtworks Holding (TWKS)

March 9, 2023 | msn.com

Citigroup Maintains Buy Rating for Longboard Pharmaceuticals: Here's What You Need To Know

March 7, 2023 | finance.yahoo.com

Wall Street Analysts Predict an 184.81% Upside in Longboard Pharmaceuticals, Inc. (LBPH): Here's What You Should Know

See More Headlines

LBPH Price History

30 days | 90 days | 365 days | Advanced Chart

LBPH Company Calendar

Last Earnings: 5/09/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/03/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LBPH
CUSIP: N/A
CIK: 1832168
Web: www.longboardpharma.com
Phone: 619-592-9775
Fax: N/A
Employees: 21
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $17.40
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $13.00
Forecasted Upside/Downside: +133.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.57)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-43,940,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.48%
Return on Assets: -56.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.91
Quick Ratio: 10.91

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.57 per share
Price / Book: 2.09

Miscellaneous

Outstanding Shares: 22,969,000
Free Float: 21,690,000
Market Cap: $171.12 million
Optionable: Not Optionable
Beta: 1.24

Key Executives

Mr. Kevin R. Lind (Age 46)
Pres, CEO, Sec. & Director
Comp: $875.13k

Ms. Brandi L. Roberts CPA (Age 48)
M.B.A., Chief Financial Officer
Comp: $568.57k

Mr. Chadwick J. Orevillo MPH
VP & Head of Operations

Megan E. Knight
Head of Investor Relations

Mr. Steven W. Spector J.D. (Age 57)
Head of Bus. Devel. & Gen. Counsel

Dr. Anne M. Danks
VP & Head of Preclinical Devel.

Dr. Jodi Parsons
VP & Head of Regulatory Affairs

Dr. Randall E. Kaye M.D. (Age 60)
Chief Medical Officer

Gus Cardenas
VP & Head of Quality Assurance

Dr. Marco Peters Ph.D.
VP & Head of Translational Science

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

LBPH Stock - Frequently Asked Questions

Should I buy or sell Longboard Pharmaceuticals stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LBPH shares.
View LBPH analyst ratings or view top-rated stocks.
What is Longboard Pharmaceuticals' stock price forecast for 2023?: 5 equities research analysts have issued 12-month price targets for Longboard Pharmaceuticals' shares. Their LBPH share price forecasts range from $13.00 to $25.00. On average, they anticipate the company's stock price to reach $17.40 in the next year. This suggests a possible upside of 133.6% from the stock's current price.
View analysts price targets for LBPH or view top-rated stocks among Wall Street analysts.
How have LBPH shares performed in 2023?: Longboard Pharmaceuticals' stock was trading at $3.26 at the beginning of the year. Since then, LBPH shares have increased by 128.5% and is now trading at $7.45.
View the best growth stocks for 2023 here.
When is Longboard Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our LBPH earnings forecast.
How were Longboard Pharmaceuticals' earnings last quarter?: Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) posted its earnings results on Tuesday, May, 9th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.59) by $0.03.
When did Longboard Pharmaceuticals IPO?: (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.

What is Longboard Pharmaceuticals' stock symbol?: Longboard Pharmaceuticals trades on the NASDAQ under the ticker symbol "LBPH."
Who are Longboard Pharmaceuticals' major shareholders?: Longboard Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (12.63%), Farallon Capital Management LLC (6.80%), Price T Rowe Associates Inc. MD (6.38%), Prosight Management LP (3.92%), Integral Health Asset Management LLC (2.53%) and CIBC Asset Management Inc (0.24%).
How do I buy shares of Longboard Pharmaceuticals?: Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Longboard Pharmaceuticals' stock price today?: One share of LBPH stock can currently be purchased for approximately $7.45.
How much money does Longboard Pharmaceuticals make?: Longboard Pharmaceuticals (NASDAQ:LBPH) has a market capitalization of $171.12 million. The company earns $-43,940,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis.
How can I contact Longboard Pharmaceuticals?: Longboard Pharmaceuticals' mailing address is 6154 NANCY RIDGE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.longboardpharma.com. The company can be reached via phone at 619-592-9775 or via email at ir@longboardpharma.com.

This page (NASDAQ:LBPH) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial